1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,350 | 1,410 | 13.10. | |
| 1,350 | 1,410 | 13.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10. | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 213 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| 22.09. | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 22.09. | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 146 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08. | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.08. | MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns | 11 | Investing.com | ||
| 07.08. | MaxCyte stock downgraded by William Blair to Market Perform on weak guidance | 2 | Investing.com | ||
| 07.08. | MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation | 1 | Seeking Alpha | ||
| 06.08. | MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges | 3 | Investing.com | ||
| 06.08. | MAXCYTE, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | 262 | GlobeNewswire (Europe) | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 31.07. | MaxCyte, Inc: MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline | 161 | GlobeNewswire (Europe) | ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 09.07. | MaxCyte, Inc: MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 | 4 | GlobeNewswire (USA) | ||
| 26.06. | XFRA MYE0: WIEDERAUFNAHME/RESUMPTION | 337 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 26.06. | XFRA MYE0: AUSSETZUNG/SUSPENSION | 194 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAXCYTE INC DL-... ► Artikel lesen | |
| 26.06. | AIM - Cancellation - Maxcyte Inc | 1 | RNS | ||
| 25.06. | MaxCyte shares trading for last time in London | 2 | Sharecast | ||
| 25.06. | MaxCyte, Inc. - Last Day of Dealings on AIM | - | RNS |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,575 | -0,60 % | Sangamo Therapeutics: Hoch spekulativ, aber mit guten Aussichten auf Kursgewinne! | ||
| IMMATICS | 8,915 | +2,06 % | Immatics Appoints Venkat Ramanan as Chief Financial Officer | Houston, Texas and Tuebingen, Germany, October 1, 2025 - Immatics N.V.as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedInand Instagram.Forward-Looking... ► Artikel lesen | |
| ALDEYRA | 4,579 | +0,97 % | Jefferies erhöht Kursziel für Aldeyra Therapeutics nach FDA-Annahme auf 7 US-Dollar | ||
| MEDIFAST | 11,440 | -0,13 % | Medifast Bolsters Growth Through Health & Wellness Solutions | ||
| PHARMING | 1,259 | +0,48 % | Pharming Group N.V.: Pharming Group provides update on previously announced G&A expense reduction plan | Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,514 | +1,48 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 21,400 | -2,73 % | Barclays initiates Oruka Therapeutics stock with Overweight rating | ||
| ARMATA PHARMACEUTICALS | 2,700 | +0,75 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update | Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02
... ► Artikel lesen | |
| INNOVIVA | 15,100 | +3,42 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | NSE - BRAINSTORM CELL THERAPEUTICS INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| DBV TECHNOLOGIES | 2,750 | +0,73 % | DBV Technologies S.A.: DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq | Châtillon, France, October 6, 2025
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
DBV Technologies (Euronext: DBV - ISIN:... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,265 | +0,61 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
| LIQUIDIA | 20,640 | +0,39 % | Liquidia Technologies, Inc.: Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 | ||
| SYNDAX PHARMACEUTICALS | 13,100 | -0,76 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,840 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
MAXCYTE INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,72 % bei einem Aktienkurs von 1,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.